Jazz Pharmaceuticals

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

Onera Health, Inc. specializes in sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, the company utilizes advanced sleep diagnostic patch systems that collect and analyze sleep data. These innovative solutions are designed to enhance patient care by providing comprehensive sleep test data to healthcare professionals across various settings, thereby improving the management of sleep-related ailments and potentially benefiting other medical fields through remote monitoring of chronic conditions. Onera Health's mission is to improve the health and quality of life for individuals struggling with sleep issues while also contributing to cost reductions in healthcare.

GW Pharmaceuticals plc is a biopharmaceutical company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of innovative therapeutics derived from its proprietary cannabinoid product platform. The company's primary product, Epidiolex, is an oral solution approved for treating seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients aged one year and older in the United States, and under the name Epidyolex in the European Union for similar indications. Additionally, GW Pharmaceuticals markets Sativex for managing spasticity due to multiple sclerosis and is advancing various cannabinoid product candidates through clinical trials targeting conditions such as schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. Established in 1998, the company operates primarily in Europe, the United Kingdom, and the United States.

Cavion LLC is a clinical-stage pharmaceutical company focused on developing therapies that restore the brain’s natural rhythms by modulating T-type calcium channels (Cav3), which are implicated in various neurological and rare genetic diseases. The company, founded in 2003 and based in Charlottesville, Virginia, with an additional office in Cambridge, Massachusetts, has developed CX-8998, a drug that targets these calcium channels in the nervous system. Cavion's innovative approach also extends to cancer treatment, as the company was the first to create therapies that engage Cav3 for solid tumors, with preclinical successes leading to Phase 1 clinical trials in brain cancer. The company's neurology program aims to deliver a novel class of non-addictive, non-opioid T-type calcium channel antagonists for conditions like neuropathic pain, essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome. Cavion operates as a subsidiary of Jazz Pharmaceuticals plc, reflecting its commitment to advancing treatments that address critical medical needs in both oncology and neurology.

Onera Health, Inc. specializes in sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, the company utilizes advanced sleep diagnostic patch systems that collect and analyze sleep data. These innovative solutions are designed to enhance patient care by providing comprehensive sleep test data to healthcare professionals across various settings, thereby improving the management of sleep-related ailments and potentially benefiting other medical fields through remote monitoring of chronic conditions. Onera Health's mission is to improve the health and quality of life for individuals struggling with sleep issues while also contributing to cost reductions in healthcare.

Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Utilizing its proprietary CombiPlex technology platform, the company designs and evaluates optimized drug combinations that integrate traditional chemotherapies with molecularly targeted agents to enhance anti-cancer efficacy. Notable products in its pipeline include VYXEOS, a nano-scale liposomal formulation of irinotecan and floxuridine, and CPX-351, a liposomal formulation of cytarabine and daunorubicin, both in Phase III clinical trials for acute myeloid leukemia. Additionally, CPX-1, a liposomal formulation of irinotecan and floxuridine, has completed Phase II studies for colorectal cancer. Celator also has a preclinical candidate, CPX-8, which is a hydrophobic docetaxel prodrug nanoparticle formulation. Founded in 1999 and headquartered in Ewing, New Jersey, Celator Pharmaceuticals operates as a subsidiary of Jazz Pharmaceuticals Public Limited Company.

Arrivo BioVentures LLC is a biopharmaceutical company based in Morrisville, North Carolina, established in 2015. The company specializes in developing biologics and small molecules aimed at enhancing patient care. Arrivo BioVentures focuses on creating reformulated biopharmaceutical drugs and new chemical entities, employing its expertise in drug development to identify effective regulatory strategies. By coordinating closely with regulatory bodies such as the FDA, the company seeks to streamline the approval process and efficiently implement clinical programs for its products. This approach minimizes potential challenges and accelerates the development timeline, ultimately contributing to improved patient outcomes.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Gentium S.p.A. is biopharmaceutical company specializing in the discovery, research, development and manufacture of active ingredients derived from natural sources as potential therapeutic agents. Gentium operates independently as a research facility and production plant for drug substance pharmaceuticals in Villa Guardia, near Como, Italy.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

Azur Pharma is a privately held pharmaceutical company focused on improving patients' lives through the development and marketing of biopharmaceutical products in specialized therapeutic areas. The company aims to identify, evaluate, and selectively acquire late-stage development and approved pharmaceutical products, enhancing their value in the process. Azur Pharma's portfolio includes treatments for conditions such as cataplexy, excessive daytime sleepiness, acute lymphoblastic leukemia, and severe hepatic veno-occlusive disease, addressing significant unmet medical needs.

Orphan Medical is a healthcare company focused on the development of specialty drugs aimed at treating sleep disorders, pain, and other central nervous system disorders. The company is dedicated to addressing unmet medical needs in these areas by creating innovative therapeutic solutions. Through its research and development efforts, Orphan Medical seeks to enhance the quality of life for patients suffering from these conditions.